Benign Prostatic Hyperplasia Treatment Market By Therapy Type (Pharmacological, Minimally Invasive Surgical Therapies, Surgical Procedures); By Procedure Setting (Hospitals, Ambulatory Surgical Centers, Urology Clinics); By End User (Hospitals & Teaching Institutions, Specialty Urology Centers, Retail & Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Benign Prostatic Hyperplasia Treatment Market: Generic Drug Volume, Procedure Durability, and Minimally Invasive Device Expansion Reshape Urology Competition

The Global Benign Prostatic Hyperplasia Treatment Market was valued at USD 12.4 billion in 2025 and is projected to reach USD 18.32 billion by 2032, growing at a CAGR of 5.73%, according to Strategic Market Research.

 

The Benign Prostatic Hyperplasia Treatment Market is commercially established, with large prescription volume anchored by alpha blockers, 5-alpha-reductase inhibitors, tadalafil, and long-standing surgical procedures. Growth is shifting toward urologist-led interventions, minimally invasive devices, robotic platforms, and procedures that reduce recovery burden while preserving durability. Drug treatment remains broad and price-sensitive, while procedural care carries higher revenue per patient and stronger supplier differentiation.

 

BPH is not a mortality-driven treatment category. Spending follows symptom burden, urinary retention, recurrent infection, drug escalation, specialist referral, and procedure use. A global burden analysis estimated 112.5 million prevalent BPH cases in 2021, and a lifetime-risk study estimated a 27.29% lifetime risk from age 40. These figures support a large ageing-linked treatment pool, but only a portion becomes commercially active through diagnosis, prescription use, urologist referral, and procedure conversion.

 

Diagnosed Older Men Create the Strongest Treatment Funnel

U.S. claims data provide the clearest view of treated-market formation. NIDDK’s Urologic Diseases in America report found BPH/LUTS claims prevalence of 5%–6% among privately insured men aged 40–64 and 29%–33% among Medicare FFS men aged 65 and older. Medicare Advantage prevalence among men aged 65 and older ranged from 31%–35% during 2015–2021. Medicare-aged men therefore represent the most identifiable treatment pool because diagnosis, prescription use, referral, and procedures are captured through reimbursed care.

New cases continue to enter treatment each year. Among Medicare FFS men aged 65 and older, NIDDK estimated average annual BPH/LUTS incidence of about 600 per 10,000 men, equal to roughly 600,000 newly identified older men each year from 2015 through 2021. Newly diagnosed patients typically enter primary-care prescribing first, then move toward urology evaluation, combination therapy, or procedural treatment when symptoms persist.

Complications move patients faster into higher-value care. In 2021, urinary retention was recorded in 8% of privately insured men aged 40–64 with BPH/LUTS and 15% of Medicare FFS men aged 65 and older. Urinary tract infection appeared in 10% and 18% of those groups, respectively. Among incident BPH/LUTS patients, 7% developed urinary retention within four years, and 23% of those patients underwent a procedure within one year of retention. Retention and recurrent infection convert BPH from routine medication management into a urologist-led intervention pathway.

 

Generic Drugs Hold Volume but Limit Pricing Power

Prescription demand is large but not universal. In 2021, 44% of diagnosed men aged 40–64 and 60% of diagnosed men aged 65 and older filled a BPH-indicated prescription. Diagnosis therefore exceeds pharmaceutical demand, as many men delay therapy, remain under observation, or manage symptoms without prescription treatment.

Alpha blockers remain the mainstay of prescription treatment. NIDDK found that alpha blockers accounted for 39% of BPH/LUTS prescription fills among diagnosed men aged 40–64 and 53% among men aged 65 and older in 2021. Among newly identified Medicare-aged patients who started medication within five years, 85% received an alpha blocker as the first drug. Tamsulosin benefits from first-line familiarity and broad generic availability, but the same generic depth limits premium pricing across the largest drug segment.

5-alpha-reductase inhibitors serve men with enlarged prostates and higher progression risk. NIDDK reported 5-ARI fills in 8% of diagnosed men aged 40–64 and 22% of men aged 65 and older. AUA guidance supports 5-ARIs alone or with alpha blockers to reduce BPH progression, acute urinary retention, and surgery risk in appropriately selected patients. Their value is tied less to rapid symptom relief and more to long-term disease modification in men at risk of progression.

Daily tadalafil occupies a smaller but differentiated position. FDA labeling supports tadalafil for BPH signs and symptoms and for men with both erectile dysfunction and BPH. NIDDK claims data show tadalafil 5 mg use in 5% of diagnosed men aged 40–64 and less than 1% of men aged 65 and older in 2021. Dual BPH/ED positioning gives tadalafil a clear use case, but alpha blockers retain the stronger role in first-line symptom management.

Fixed-dose combinations are generally reserved for selected patients. Entadfi combines finasteride and tadalafil and is FDA-approved to initiate treatment of BPH signs and symptoms in men with enlarged prostate for up to 26 weeks. Duration limits, generic substitution, and payer behavior restrict broad use, but the product reflects continued interest in combining symptom relief, progression control, and sexual-function positioning in one regimen.

 

Procedures Carry Higher Value but Require Stronger Patient Conversion

BPH procedures account for a smaller share of treated patients but generate higher revenue per intervention. NIDDK found average annual BPH/LUTS procedure use of 1.7% among diagnosed men aged 40–64 and 2.4% among men aged 65 and older from 2012 to 2021. In the 2015 incident Medicare-aged cohort, 7.0% underwent a BPH-related procedure within five years. Device manufacturers should therefore focus on diagnosed symptomatic patients who fail medication or develop complications, not the full epidemiological BPH population.

TURP remains the benchmark for durability and reimbursement comparison. Among incident Medicare-aged patients who underwent a first BPH procedure within five years, TURP accounted for 50% of initial procedures, followed by laser prostatectomy at 22% and prostatic urethral lift at 12%. Minimally invasive procedures have gained share, but transurethral tissue-removing surgery still sets the standard for symptom improvement and retreatment expectations.

Urologists control the main conversion point. NIDDK reported that 53% of incident BPH/LUTS patients had an evaluation and management visit with a urologist within five years, with the average time to urologist visit under seven months. After urologist consultation, 9% underwent a procedure within the following two years. Device adoption depends on physician training, local procedure economics, payer coverage, office workflow, and confidence in durability.

 

Durability Determines the Real Value of Minimally Invasive Therapies

Minimally invasive surgical therapies compete on outpatient delivery, shorter recovery, lower anesthesia burden, and preservation of sexual function. Retreatment risk remains the main constraint. NIDDK reported a 5.0% two-year retreatment rate after BPH-related procedures in the incident cohort, with retreatment at 11.0% after minimally invasive surgical therapy compared with 3.3% after transurethral procedures. Payers and urologists weigh the lower care burden of MIST against the cost of repeat intervention.

Prostatic urethral lift shows the commercial trade-off clearly. UroLift’s strength is outpatient delivery, sexual-function preservation, and avoidance of tissue removal in selected patients. Its weakness is durability compared with tissue-removing procedures. The pivotal L.I.F.T. study reported 13.6% surgical retreatment over five years, while a real-world analysis found four-year reprocedure rates of 16.1% after UroLift versus 7.5% after TURP and 7.8% after photovaporization.

Water-vapor thermal therapy has expanded its eligible prostate range. FDA’s 2025 Rezum 510(k) record supports use in men aged 50 or older with prostate volume 30–150 cm³, including central zone and/or median lobe hyperplasia. A broader indication increases Rezum’s competitive reach, but adoption still depends on anatomy, retention history, local anesthesia capability, physician preference, and payer coverage.

 

Aquablation Builds a Premium System-and-Consumables Model

Aquablation has created one of the clearest premium medtech positions in BPH treatment. FDA classified the AquaBeam System as a Class II fluid jet system for prostate tissue removal in 2017, supporting a model built around robotic capital equipment, image-guided planning, procedural precision, and disposable handpiece use.

PROCEPT BioRobotics’ 2026 results show how this model scales commercially. In Q1 2026, the company reported USD 83.1 million in revenue, about 12,200 U.S. procedures, 765 U.S. installed systems, and USD 43.0 million in U.S. handpiece and consumable revenue. Capital placement gives hospitals the platform, while handpieces and consumables create recurring revenue tied to procedure volume.

Large-prostate treatment remains a strategic test for Aquablation. The WATER III trial is comparing Aquablation with transurethral laser enucleation in prostates of approximately 80–180 mL, with planned enrollment around 202 patients. Positive comparative evidence would strengthen Aquablation in cases where HoLEP and other enucleation approaches already compete on durability, gland-size flexibility, and specialist outcomes.

 

New Implants and Drug-Coated Balloons Increase Category Competition

FDA approvals in 2025 increased competition in implant-based BPH therapy. The ProVee System received FDA PMA approval in December 2025 for obstructive LUTS secondary to BPH in men with prostatic urethral lengths of at least 3.75 cm and prostate volumes 30–80 cc. The Zenflow Spring Implant and Delivery System received FDA PMA approval for men with prostatic urethral lengths 25–45 mm and prostate sizes 25–80 cc. More implant choices give urologists additional anatomy-specific options, but also raise the standard for comparative evidence on durability, sexual outcomes, removability, retreatment, and reimbursement.

Optilume BPH adds a drug-coated balloon approach to the procedure mix. FDA approved the Optilume BPH Catheter System in 2023 for obstructive urinary symptoms associated with BPH in men aged 50 and older. Laborie reported that the American Medical Association issued a Category I CPT code for Optilume BPH effective January 1, 2026. Coding improves the infrastructure for U.S. adoption, but coverage policy, site-of-care economics, and comparative results against Rezum, UroLift, TURP, and laser procedures will determine uptake.

Ownership and pricing pressure are visible in the UroLift business. Teleflex recorded impairment charges tied to its Interventional Urology North America unit in 2024 and 2025 and later agreed to sell its Acute Care, Interventional Urology, and OEM businesses for USD 2.03 billion. UroLift’s experience shows that clinical recognition does not protect an office-based device from reimbursement pressure, slower growth, pricing challenges, and stronger competition.

 

Device Innovation Is Moving Faster Than Drug Development

Low-cost generics limit the opportunity for new BPH drugs. GV1001 represents a pharmaceutical differentiation attempt in moderate-to-severe BPH, with a completed Korean Phase 3 study, but no FDA or EMA approval was identified. New drug entrants must show a clear advantage over alpha blockers, 5-ARIs, tadalafil, and established combination therapy without adding cost or tolerability barriers.

Device development remains more active because urologists continue to look for procedures that reduce recovery burden without sacrificing durability. Butterfly Medical completed final 12-month follow-up in a 244-patient pivotal study of its Prostatic Retraction Device in January 2026, supporting a planned FDA PMA submission. HistoSonics began treating patients in the WOLVERINE feasibility trial of the Edison histotripsy system for BPH in Hong Kong in 2026. These programs point toward anatomy-preserving, less-invasive, and potentially non-invasive approaches, although commercial adoption will depend on long-term symptom relief, retreatment rates, procedural workflow, and payer acceptance.

 

Regional Market Behavior

North America remains the leading commercial region because the United States combines a large Medicare-aged diagnosed population, strong urology referral infrastructure, multiple FDA-approved procedure categories, and high adoption of branded medtech platforms. Disease prevalence is not the limiting factor in the U.S.; conversion depends on symptom severity, medication failure, payer authorization, site-of-care economics, and physician training.

Europe is a mature procedural market shaped by guideline discipline and health-technology assessment. EAU guidance keeps TURP, HoLEP, laser procedures, water-vapor therapy, prostatic urethral lift, prostatic artery embolization, and Aquablation within a comparative framework based on prostate size, durability, perioperative morbidity, and retreatment. Germany’s large surgical base and the UK’s focus on day-case efficiency favor technologies that reduce hospitalization, catheter time, and operating-room burden without weakening outcomes.

Asia-Pacific offers the largest long-term patient-pool expansion, but served-market conversion varies sharply by country. South Korea’s national claims data showed newly diagnosed LUTS/BPH patients rising from 196,948 in 2012 to 255,803 in 2017, reflecting strong insured demand. India had an estimated 18.2 million BPH cases in 2019, but diagnosis rates, affordability, specialist access, and procedural infrastructure narrow the commercially served population.

 

Market Outlook

BPH treatment will remain split between high-volume generic medication and higher-value procedural care. Alpha blockers will continue to dominate prescription starts because they are fast-acting, low-cost, and entrenched in primary care and urology practice. 5-ARIs and combination therapy will retain value in enlarged prostates and progression-prone patients. Tadalafil and Entadfi will compete where dual BPH/ED use, sexual-function considerations, or combination convenience influence prescribing.

Procedural competition will become more evidence-sensitive. TURP and laser surgery will remain durability benchmarks. HoLEP and other enucleation approaches will hold strength in larger glands and specialist centers. Rezum, UroLift, iTind, Optilume BPH, ProVee, Zenflow, Butterfly, and other minimally invasive systems will compete on outpatient delivery, recovery time, sexual-function preservation, anatomy fit, and procedural simplicity. Retreatment data will matter as much as early symptom improvement.

Aquablation has the strongest premium-system profile because it combines robotic capital placement with recurring handpiece revenue. PROCEPT’s installed-base growth, procedure volume, and consumable revenue show that BPH medtech can scale when clinical differentiation is tied to repeat procedural economics. Future share gains across the category will depend on durability, coding, payer coverage, site-of-care fit, sexual-function outcomes, physician training, and comparative evidence against TURP, HoLEP, and established minimally invasive therapies.

 

Benign Prostatic Hyperplasia Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 12.4 Billion
Revenue Forecast in 2032	USD 18.32 Billion
Overall Growth Rate	CAGR of 5.73% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Therapy Type, By Procedure Setting, By End User, By Geography
By Therapy Type	Pharmacological Therapy, Minimally Invasive Surgical Therapies, Surgical Procedures
By Procedure Setting	Hospitals, Ambulatory Surgical Centers, Urology Clinics
By End User	Hospitals & Teaching Institutions, Specialty Urology Centers, Retail & Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Rising ageing male population Increasing diagnosis of lower urinary tract symptoms (LUTS) Growing demand for minimally invasive BPH procedures
Customization Option	Available upon request